金龙胶囊对耐紫杉醇及长春新碱肿瘤细胞株的逆转及增敏作用

Effect of Jinlong Capsules on Reversing Paclitaxel-resistance Vincritine-resistance and Enhancing Sensitivity in Human Cancer Cell Lines

目的评价抗肿瘤复方中药金龙胶囊对耐紫杉醇及长春新碱(VCR)肿瘤细胞的逆转及增敏活性。方法测定金龙胶囊对四种耐药细胞(人肺腺癌耐紫杉醇细胞A549/Paclitaxel、人乳腺癌耐紫杉醇细胞MX-1/Paclitaxel、人口腔上皮癌耐长春新碱细胞KB/V、人肝癌耐5-氟尿嘧啶细胞Bel7402/5-Fu)及相应亲本细胞的IC50,然后将无毒浓度金龙胶囊与化疗药合用,评价其对各细胞获得性耐药、交叉耐药和内在耐药的逆转活性及细胞增敏作用。结果 100、200、400μg/ml金龙胶囊对A549/Paclitaxel细胞对Paclitaxel的获得性耐药有一定逆转活性,最高达10.64倍;50、100、200μg/ml金龙胶囊在MX-1细胞对Paclitaxel及VCR均显示一定增敏活性,最高达12.61,且有量效关系;200μg/ml金龙胶囊对Bel7402/5-Fu细胞对VCR的内在耐药具有一定增敏作用,达4.03倍。结论金龙胶囊具有一定化疗耐药逆转和化疗增敏潜能,并且有细胞选择性和化疗药物选择性。

Objective To investigate the effect of Jinlong Capsules on reversing paclitaxel-resistance,vincristineresistance and enhancing sensitivity in human cancer cell lines. Methods MTT assay was adopted to test cytotoxicity, sensitization and MDR reversing of Jinlong Capsules in paclitaxel-resistant lung adenocarcinoma cell line, paclitaxel-resistant breast cancer cell line, vincristine-resistant squamous carcinoma cell line, fluorouracil-resistant hepatocarcinoma cell line and the parent cells. Reversal fold was calculated from median inhibitory concentration(IC50). Results Jinlong Capsules showed no obvious selectivity among these different cell lines, and IC50 was kept at 1.5 ~5.2 mg/ml. In paclitaxel-resistant lung adenocarcinoma cell line, Jinlong Capsules reversed the acquired drug-resistance at a dosage of 100, 200 and 400 μg/ml, with a reversal fold of 2.25, 2.99 and 10.64. In paclitaxel-resistant breast cancer cell line, Jinlong Capsules enhanced its sensitivity at a dosage of 50, 100 and 200 μg/ml, and the highest sensitization fold reached up to 12.61. In fluorouracil-resistant hepatocarcinoma cell line, Jinlong Capsules enhanced its sensitivity at a dosage of 200 μg/ml, with a fold change of 4.03. Conclusion Jinlong Capsules could reverse MDR and enhance the sensitivity in drug-resistant human tumor cells in a certain extent, accompanied with a selectivity in cell lines and chemotherapy drugs.